-
Mashup Score: 4
In the interview, Alexander Helfand, MD reviewed the latest in gastrointestinal stromal tumor research, and hopes for the future.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0First- and Later-Line Therapies in Patients With GIST - 5 month(s) ago
Domenech Asbun, MD, discusses first-, second-, and later lines of therapy for patients with gastrointestinal stromal tumor.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Domenech Asbun, MD, discusses first-, second-, and later lines of therapy for patients with #GIST. @BHCancerCare https://t.co/P5mRedPkyG
-
-
Mashup Score: 0
Antonio Ucar, MD, explains the rationale behind the phase 3 Peak study of bezuclastinib plus sunitinib in patients with gastrointestinal stromal tumors being treated in the second-line setting.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video, Antonio Ucar, MD, discusses the phase 3 Peak study of bezuclastinib + sunitinib in patients with #GIST being treated in the second-line setting. @BaptistHealthSF @BHCancerCare @MiamiCancerInst https://t.co/VcJqStfAyt
-
-
Mashup Score: 1
In the interview, Alexander Helfand, MD reviewed the latest in gastrointestinal stromal tumor research, and hopes for the future.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
As treatment options for #GIST advance, now is the perfect time to keep up with the latest research. Check out this interview with Alexander Helfand, MD of @AHNtoday, to learn about promising research to improve care for patients: https://t.co/rGBpHPGrzA.
-
-
Mashup Score: 1Olverembatinib Demonstrates Promising Outcomes in SDH-Deficient GIST - 8 month(s) ago
Experts say results from a phase 1 study of olverembatinib in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor were encouraging and warrant further research.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"Olverembatinib may offer a new treatment option to patients with SDH-deficient #GIST, a highly rare subtype of GIST that currently lacks standard of care treatment," said Ruihua Xu, MD, PhD. https://t.co/awoEpB9Oy6
-
-
Mashup Score: 0Bezuclastinib/Sunitinib Shows Early Promise in Second-Line GIST - 9 month(s) ago
In an interview with Targeted Oncology, Antonio Ucar, MD, discussed the evolving role of sunitinib for the second-line treatment of gastrointestinal stromal tumors, and the Peak study.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Antonio Ucar, MD, on the evolving role of sunitinib for the second-line treatment of #GIST. #gicsm | @BaptistHealthSF @BHCancerCare @MiamiCancerInst https://t.co/CAwQiWin00 https://t.co/txBhzG2l7n
-
-
Mashup Score: 0Advice and Future Directions for the Treatment of GIST - 9 month(s) ago
Edwin Choy, MD, provides key recommendations for community oncologists treating patients with gastrointestinal stromal tumor.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Edwin Choy, MD, provides key recommendations for community oncologists treating patients with #GIST. @MGHCancerCenter https://t.co/SqwNb2MtZo
-
-
Mashup Score: 1Phase 3 Study Evaluates Ripretinib for KIT Exon 11-Mutated GIST - 9 month(s) ago
Ripretinib will be evaluated in a phase 3 trial for patients with gastrointestinal stromal tumor after being added to the NCCN guidelines and receiving 2 breakthrough therapy designations from the FDA.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The phase 3 INSIGHT trial is evaluating ripretinib vs sunitinib for patients with #GIST who progressed on first-line treatment with imatinib and harbor co-occurring KIT exons 11+17/18 mutations. @royalmarsdenNHS https://t.co/CDk1aObLvi
-
-
Mashup Score: 1First- and Second-Line Treatments for Patients With GIST - 10 month(s) ago
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to Edwin Choy, MD of @MGHCancerCenter, some of treatment options for patients with #GIST include sunitinib, regorafenib, ripretinib, avapritinib, and imatinib. https://t.co/D2We95huJt
-
-
Mashup Score: 0Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gastrointestinal stromal tumors (GIST) is a rare type of stomach cancer. Approximately one in six patients develop additional malignancies after #GIST diagnosis. Further studies are needed to understand the connection between GIST and other #cancers. https://t.co/jhDHneTUk9 https://t.co/QgYvq3yGFs
-
As treatment options for #GIST advance, now is the perfect time to keep up with the latest research. Check out this interview with Alexander Helfand, MD of @AHNtoday, to learn about promising research to improve care for patients: https://t.co/rGBpHPGrzA.